Approval · Notice of Compliance 26047 · 2021
RIZATRIPTAN: Notice of Compliance 26047
Issued June 11, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26047
- Date
- June 11, 2021
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIZATRIPTAN | 02516721 | Approved |
| RIZATRIPTAN | 02516756 | Marketed |
Medicinal ingredients
- RIZATRIPTAN 5 MG per TAB
- RIZATRIPTAN 10 MG per TAB